FUSMobile advances non-invasive solutions for the treatment of chronic painful conditions that improve the patient experience and clinical outcomes while reducing costs for healthcare providers and payers.
The Neurolyser is a focused ultrasound treatment platform designed with the potential to relieve suffering from a range of common conditions, including chronic low back (facet joint) pain, knee and hip arthritis, sacroiliitis, and bone metastases.
Once approved, the Neurolyser has the potential to disrupt the rapidly growing interventional pain management market by offering a completely non-invasive solution to thermally ablate nerves without the risks, pain, higher costs or extensive training required by more invasive methods.
Growing Clinical Experience
The Neurolyser XR focused ultrasound device has finished its first in human study with excellent results and will soon enter pivotal clinical trials in pursuit of North American regulatory approval for facet joint arthritis, the first of many pain-related indications with potential benefits over currently available interventional pain treatments.
FUSMobile’s go-to-market strategy minimizes barriers and improves economic incentives to accelerate adoption by key stakeholders in the healthcare ecosystem. The company has secure intellectual property and is well-positioned for utilization and reimbursement.
Supported by medical investment leaders OrbiMed Advisors, FUS Mobile is currently initiating the pivotal studies in the US and Canada, regulatory filing, scaling for commercialization and ongoing R&D.
FUSMobile was founded by a team of experts with deep understanding of focused ultrasound and experience in bringing emerging medical technologies to market. The company’s advisors include internationally recognized luminaries in the field.
Co-Founder and CEO, Director
Dr. Hananel has nearly 20 years of experience in focused ultrasound. As the Medical and Scientific Director for the Focused Ultrasound Foundation he collaborated with academia and industry on clinical trial design, conducted feasibility research at the University of Virginia Focused Ultrasound Center and served as an ambassador for the technology to scientific and clinical communities. He previously spent 12 years at InSightec Ltd, where he served as director of clinical research outside the US and program bone manager, overseeing development, clinical trials, training and commercialization of the technology for a multiple indications. He has also served as a board member for the International Society of Therapeutic Ultrasound, Co-Editor-in-Chief for the Journal of Therapeutic Ultrasound, and visiting assistant professor at UVA. Dr. Hananel received his MBA and his MD from Tel-Aviv University.
Co-Founder and President, Director
Mr. Aginsky has nearly 20 years of expertise in medical device development, with emphasis on market development and penetration strategy, sales and marketing, implementation of reimbursement projects and corporate law. Prior to founding FUSMobile, he spent 12 years with focused ultrasound company InSightec Ltd, where he grew to serve on the management team as Vice President for European Markets, in charge of market penetration strategy with a wide range of activities from research collaborations to new product introduction. He was previously with Elscint Ltd., a public technology company that develops medical imaging solutions, where he provided legal counsel on interactions with worldwide subsidiaries and other business matters. Mr. Aginsky studied law at Coventry University in the UK and received his MBA from the Arison School of Business at IDC Herzliya.